SCHEMBL718504

SCHEMBL718504

CCc1oc2ccccc2c1C(Cl)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 5/20 0.43
VKORC1 Q9BQB6 2/20 0.42
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 4/20 0.36
KDM4E B2RXH2 3/20 0.36
EYA3 Q99504 2/20 0.36
SLC22A12 Q96S37 1/20 0.36
MEN1 O00255 3/20 0.36
HTT P42858 2/20 0.36
TP53 P04637 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
USP2 O75604 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719970 0.84 CYP2C19 (0.49) CYP2C19VKORC1KMT2AALDH1A1MAPT
SCHEMBL716824 0.73 NPC1 (0.48) CYP2C19VKORC1KMT2AALDH1A1MAPT
SCHEMBL14299512 0.73 CYP2C19 (0.54) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL11637773 0.68 CYP2C19 (0.49) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL4806386 0.67 CYP2C19 (0.69) CYP2C19VKORC1ALDH1A1HSD17B10KDM4E
SCHEMBL11637488 0.67 CYP2C19 (0.48) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL3099505 0.67 KDM4E (0.33) ALDH1A1NPC1RAB9AKDM4ETSHR
Hydrochloric Acid SCHEMBL11637777 0.66 CYP2C19 (0.50) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL11638728 0.66 CYP2C19 (0.47) CYP2C19KMT2AALDH1A1MAPTHPGD
SCHEMBL11640926 0.66 CYP2C19 (0.50) CYP2C19KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP2C19 946/4885VKORC1 513/4885KMT2A 1298/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP2C19 946/4885VKORC1 513/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.